STAT+: Pharmalittle: Wir lesen über ein Telemedizinunternehmen und die Patientensicherheit, übermäßige Gebühren für PBMs und mehr

LifeMD, a telehealth company promoted by Novo Nordisk, has faced allegations from former employees who claim the firm prioritized profit over patient safety. According to five current and former staff members interviewed by STAT and two lawsuits filed by former senior executives, LifeMD pressured its clinicians to process more patients and issue prescriptions quickly, often without adequate screening or follow-up. The company, which denies the accusations, operates within a broader network of GLP-1 telehealth firms that have gained momentum due to the success of weight-loss medications like Ozempic and Wegovy. LifeMD is part of a growing sector of telehealth services that provide access to GLP-1 drugs, which are used to treat type 2 diabetes and obesity. These services are increasingly popular as newer, more potent versions of such drugs become available. Novo Nordisk, the manufacturer of Ozempic and Wegovy, lists LifeMD on its official website as a trusted partner offering “legitimate medicine sourcing and patient support.” However, insiders paint a different picture, describing the company as one that incentivizes high prescription volumes at the potential cost of medical thoroughness. According to former employees, clinicians were expected to handle up to 25 patient cases per hour, reviewing only electronic forms completed by patients. This equates to approximately two minutes spent per case, raising concerns about the depth of medical evaluation. Some workers stated that they were instructed not to ask what they considered medically necessary questions during consultations, to avoid delaying care. Such practices, if true, suggest a systemic pressure to increase throughput rather than ensure comprehensive care. The situation highlights ongoing challenges in the regulation of telehealth services, particularly those linked to high-stakes medications. Experts warn that the rapid expansion of these services, driven by both pharmaceutical companies and demand for effective treatments, may lead to compromised clinical oversight. With more powerful obesity drugs entering the market, there is concern that inadequate monitoring could result in serious adverse effects among patients. In response to the allegations, LifeMD has issued statements denying the claims, asserting that its operations adhere to all applicable standards and regulations. The company has not publicly commented on specific employee accounts or legal actions brought against it. However, the controversy has sparked wider discussions about the responsibilities of pharmaceutical firms in overseeing the quality of care delivered through affiliated or partnered telehealth platforms. Legal proceedings involving LifeMD include two lawsuits initiated by former top leadership, alleging violations of professional conduct and ethical standards. While the outcomes of these cases remain pending, the allegations underscore a growing scrutiny of how pharmaceutical companies interact with and influence the delivery of healthcare services through third-party providers. As the regulatory landscape continues to evolve, the balance between innovation and accountability will remain a critical focus for policymakers and health professionals alike.